Pfizer (PFE) Earnings Take: Watch Obesity, Oncology Trials and Generic Pressure

Pfizer (PFE) reported Q4 revenue exceeding expectations despite a U.S. vaccine recommendation narrowing and year-over-year sales declines, with operating margins contracting. The stock closed at $27.03, up from $26.66 pre-earnings. Analysts will closely monitor: (1) progression of phase 3 trials in obesity and oncology; (2) pressure from generics on non-COVID revenue and the company’s ability to stabilize those streams; (3) implementation of AI to drive operational efficiencies; and (4) upcoming launches and regulatory milestones in chronic weight management and rare disease.